Jack Taunton, PhD
Professor, Cellular Molecular Pharmacology, UCSF
My laboratory develops chemical and biochemical tools to illuminate cellular processes relevant to cancer and autoimmune disease. In a major project area, we have designed covalent inhibitors that target protein kinases with extraordinary selectivity. These inhibitors exploit a non-catalytic cysteine in the active site of kinases such as RSK, MSK, NEK2, and BTK. We recently invented a novel and general strategy for targeting cysteines with reversible covalent inhibitors. This strategy has led to the first reversible covalent BTK inhibitors, and a drug candidate derived from these inhibitors is in Phase 2 clinical trials. In a second project, we have discovered a family of cyclic depsipeptides that inhibit the biogenesis of a subset of secreted and membrane proteins involved in cancer and inflammation. Mechanism of action studies revealed that these compounds, termed “cotransins," are direct allosteric modulators of the Sec61 translocon. Cotransins represent a promising series of anti-cancer drugs with an unprecedented mechanism of action.
Trinity University, B.S., 06/89, Chemistry
Harvard University, Ph.D., 06/96, Chemistry
Harvard Medical School, Postdoc, 96-2000, Cell Biology